Solid Biosciences to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced it will participate in two investor conferences in November 2025. Dr. Gabriel Brooks, Chief Medical Officer will join a panel titled “Precision Medicine: DMD, FA, and Beyond” on November 6, 2025 at 1:40 p.m. ET at the Truist Securities BioPharma Symposium. Management will hold one-on-one investor meetings at the 2nd Annual Guggenheim Healthcare Innovation Conference on November 10, 2025. Institutional investors should contact their Truist or Guggenheim representatives to request meetings.

News Market Reaction

-3.28%

1 alert

-3.28% News Effect

On the day this news was published, SLDB declined 3.28%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CHARLESTOWN, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:

• 2025 Truist Securities BioPharma Symposium
  Dr. Gabriel Brooks, Chief Medical Officer, will participate in a panel discussion titled “Precision Medicine: DMD, FA, and Beyond” on Thursday, November 6, 2025, at 1:40 p.m. ET.

• 2^nd Annual Guggenheim Healthcare Innovation Conference
  Members of management will participate in 1x1 investor meetings on Monday, November 10, 2025.

Institutional investors interested in one-on-one meetings with management during the conferences may reach out to their Truist or Guggenheim representatives.

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

When will Solid Biosciences (SLDB) present at the Truist Securities BioPharma Symposium?

Dr. Gabriel Brooks will participate in a panel on November 6, 2025 at 1:40 p.m. ET.

What panel will Solid Biosciences (SLDB) cover at the Truist symposium?

The panel is titled “Precision Medicine: DMD, FA, and Beyond.”

When will Solid Biosciences (SLDB) hold investor meetings at the Guggenheim Healthcare Innovation Conference?

Management will hold one-on-one investor meetings on November 10, 2025.

How can institutional investors request one-on-one meetings with Solid Biosciences (SLDB)?

Institutional investors should contact their Truist or Guggenheim representatives to schedule meetings.

Will Solid Biosciences (SLDB) webcast the Truist panel or Guggenheim meetings?

The announcement lists in-person participation and one-on-one meetings; no webcast was mentioned.

Who is representing Solid Biosciences (SLDB) at the November 2025 conferences?

Dr. Gabriel Brooks will appear on the Truist panel and members of management will attend meetings at Guggenheim.